Note that all patients received HCQ and azithromycin. Quoting the article (which I hope all here will read), "[typically] more than 40 % of patients hospitali

Note that all patients received HCQ and azithromycin. Quoting the article (which I hope all here will read), "[typically] more than 40 % of patients hospitalized because of COVID‐19 pneumonia developed ARDS of which more than 50 % ultimately died." That's a 20% fatality rate. Of the 76 patients in this study - regardless of vitamin D treatment - only 2 died, and the rest were eventually discharged. This is an outstanding result. None (!) of the hospitalized patients died in the vitamin D / HCQ / AZ group. I will say that the average age - 58 - is rather young. Only 19 out of 76 were over 60. "All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 hours on the first day, and 200 mg every 12 hours for the following 5 days), azithromycin (500 mg orally for 5 days) and for patients with pneumonia and NEWS score≥5, a broad spectrum antibiotic (ceftriaxone2 g intravenously every 24 hours for 5 days) was added to hydroxychloroquine and azithromycin." They have since discontinued HCQ because they felt that studies had shown that it was ineffective. We shall see. As with AIDS, it's the cocktail of drugs that appears to matter. What is effective pre-hospitalization (i.e. prophylactic) is different from the best protocol post-admission. And that, in turn, differs from the best course of treatment in the ICU. The improvement in outcomes over the last few months is a result of experience: https://covid19criticalcare.com/wp-content/uploads/2020/07/FLCCC_Alliance-MATHplus_Protocol_v5-2020-07-14.pdf https://covid19criticalcare.com/wp-content/uploads/2020/07/F... (pdf)